Rallybio Targets Nov. 20 Merger Close, Updates $13.90 Cash Distribution
Rallybio expects to complete its merger after November 20, 2026, and distribute $13.90 per share in cash to eligible stockholders and warrant holders on November 30, according to a regulatory filing. The distribution is subject to Nasdaq due bill procedures and merger conditions.
How this was made

The 30-second read
Why it matters
The disclosure provides a clear timeline for investors, creating a short‑term trading opportunity around the distribution.
Market read
The announcement is a primary corporate action that may drive short‑term price movement.
What to watch
Potential tax implications of the cash distribution for pre-funded warrant holders.
Background
Rallybio filed an 8‑K detailing the expected merger close and cash distribution dates.
Ticker impact
Rallybio announced its merger will close on Nov 20 and a $13.90 per-share cash distribution to be paid on Nov 30.
likely upward pressure as investors anticipate the cash distribution and merger completion
Cash distributions and merger closings typically generate buying interest; the timing is near-term.
Market effects
The biotech merger may signal continued consolidation activity in the sector.
Limited to U.S. markets where Rallybio trades.
Minimal global impact beyond niche biotech investors.
Counterpoint
If the merger faces unexpected regulatory hurdles, the stock could face downside despite the announced dates.
Key entities
- CompanyRallybio Corp
Biotech company completing a merger and issuing a cash distribution.